CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
Dry powder mannitol +3 moredrug
Likely dose
Budesonide 400mcg administered via turbuhalerfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00117182
NCT00117182Phase 2Completed
CompareCT.gov

A Phase II Study to Investigate Mannitol Challenge as a Tool to Predict Treatment Response to Inhaled Corticosteroids in COPD

Syntara·interventional·Posted Jul 4, 2005·Updated Apr 20, 2016

In Brief

A Phase 2 clinical trial evaluating Dry powder mannitol, Budesonide 400mcg administered via turbuhaler, and 2 other interventions for Lung Diseases, Obstructive. Completed, across 13 sites.

Detailed Summary

The purpose of this study is to determine whether the Aridol (mannitol) challenge test can predict response to treatment with inhaled corticosteroids in COPD subjects. Subjects will undergo an Aridol test and then 3 months of treatment with inhaled corticosteroids. The effect on lung function and quality of life will then be measured and correlated with the Aridol test result.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Diseases, Obstructive
CountriesAustralia
Collaborators--

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 4, 2005
Enrollment StartJul 1, 2005
Study CompletionAug 1, 2006
TodayJul 2, 2026
Posted 21.0 years ago

Interventions

Dry powder mannitoldrug

Budesonide 400mcg administered via turbuhalerdrug

Ipratropium bromide 80mcgdrug

Salbutamol 400mcgdrug